MDSCs obtained from these experimental models have been shown to inhibit the activity of CD8+ T cells [21,22,28,29,30,31,35], stimulate tumor angiogenesis [21], contribute to premetastatic niche formation [22,23], and increase the stem-like properties of cancer cells [29,30], all of which can promote tumor progression by facilitating tumor growth, metastasis [22], and resistance to anticancer treatments, including chemotherapy and radiotherapy [21,28]. Here, CD8A is linked to neoplasm.